Clinical trial
A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus
NCT00473382 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- September 30, 2012
- Enrollment
- 382 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.